These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38125396)

  • 21. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Herd immunity: challenges and the way forward in Korea.
    Oh J; Kim S; Ryu B; Shin M; Kim BI
    Epidemiol Health; 2021; 43():e2021054. PubMed ID: 34412446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling herd immunity requirements in Queensland: impact of vaccination effectiveness, hesitancy and variants of SARS-CoV-2.
    Sanz-Leon P; Hamilton LHW; Raison SJ; Pan AJX; Stevenson NJ; Stuart RM; Abeysuriya RG; Kerr CC; Lambert SB; Roberts JA
    Philos Trans A Math Phys Eng Sci; 2022 Oct; 380(2233):20210311. PubMed ID: 35965469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Will an imperfect vaccine curtail the COVID-19 pandemic in the U.S.?
    Iboi EA; Ngonghala CN; Gumel AB
    Infect Dis Model; 2020; 5():510-524. PubMed ID: 32835142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of Real-World Vaccination Effectiveness of mRNA COVID-19 Vaccines against Delta and Omicron Variants in Japan.
    Kodera S; Rashed EA; Hirata A
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study.
    Kucharski AJ; Klepac P; Conlan AJK; Kissler SM; Tang ML; Fry H; Gog JR; Edmunds WJ;
    Lancet Infect Dis; 2020 Oct; 20(10):1151-1160. PubMed ID: 32559451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study.
    Qassim SH; Chemaitelly H; Ayoub HH; Coyle P; Tang P; Yassine HM; Al Thani AA; Al-Khatib HA; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    EClinicalMedicine; 2023 Aug; 62():102102. PubMed ID: 37533414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants.
    Moghnieh R; El Hajj C; Abdallah D; Jbeily N; Bizri AR; Sayegh MH
    Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
    Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
    Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination.
    Yoo J; Kim Y; Cha YM; Lee J; Jeong YJ; Kim SH; Maragakis LL; Lee S
    J Infect Public Health; 2023 Oct; 16(10):1537-1543. PubMed ID: 37562081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
    Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
    Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Sonabend R; Whittles LK; Imai N; Perez-Guzman PN; Knock ES; Rawson T; Gaythorpe KAM; Djaafara BA; Hinsley W; FitzJohn RG; Lees JA; Kanapram DT; Volz EM; Ghani AC; Ferguson NM; Baguelin M; Cori A
    Lancet; 2021 Nov; 398(10313):1825-1835. PubMed ID: 34717829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review.
    Arabi M; Al-Najjar Y; Sharma O; Kamal I; Javed A; Gohil HS; Paul P; Al-Khalifa AM; Laws S; Zakaria D
    BMC Infect Dis; 2023 Jun; 23(1):432. PubMed ID: 37365490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 Seroprevalence in Canada Modelling Waning and Boosting COVID-19 Immunity in Canada a Canadian Immunization Research Network Study.
    Dick DW; Childs L; Feng Z; Li J; Röst G; Buckeridge DL; Ogden NH; Heffernan JM
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers.
    Ntziora F; Kostaki EG; Karapanou A; Mylona M; Tseti I; Sipsas NV; Paraskevis D; Sfikakis PP
    Vaccine; 2022 Nov; 40(50):7195-7200. PubMed ID: 36150972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modelling the effects of social distancing, antiviral therapy, and booster shots on mitigating Omicron spread.
    Lee J; Mendoza R; Mendoza VMP; Lee J; Seo Y; Jung E
    Sci Rep; 2023 Apr; 13(1):6914. PubMed ID: 37106066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
    He X; Su J; Ma Y; Zhang W; Tang S
    Front Immunol; 2022; 13():945930. PubMed ID: 36090988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.